You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾誠健華(688428.SH)重獲奧布替尼全球權利

格隆匯2月15日丨諾誠健華(688428.SH)公佈,2021年7月,公司與Biogen Inc.(以下簡稱“渤健”)就有望治療多發性硬化症(MS)和其他自身免疫性疾病的口服小分子布魯頓酪氨酸激酶抑制劑(BTK)奧布替尼的全球開發和商業化達成合作和許可協議,約定公司將奧布替尼在多發性硬化症(MS)領域的全球獨家權利以及除中國(包括香港、澳門和台灣)以外區域內的某些自身免疫性疾病領域的獨家權利授予渤健。根據協議約定,渤健已向公司一次性支付不可退還和不予抵扣的首付款1.25億美元。

近日,渤健已通知公司,決定為便利而終止(Terminate for Convenience)雙方達成的上述合作和許可協議,公司將重獲許可協議項下授予渤健的所有全球權利,包括相關知識產權、研發決策權、生產和商業化權益,以及源自奧布替尼的商業收益。公司與渤健將在90日內完成權益過渡。

公吿稱,奧布替尼治療多發性硬化症(MS)的II期臨牀研究仍在進行中,公司預計2023年第二季度公佈中期分析結果。基於奧布替尼在多種自身免疫性疾病臨牀試驗中取得的令人鼓舞的結果,公司對奧布替尼依然充滿信心,並將加速推進奧布替尼作為潛在同類最佳BTK抑制劑在多發性硬化症(MS)和其他自身免疫性疾病中的全球臨牀開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account